Prescient Therapeutics locks in two licenses for new cell therapy tech

Anti-cancer biotech company Prescient Therapeutics (PTX) has received two key licences to build a new cell therapy platform.

Prescient revealed today it has received an exclusive licence from the University of Pennsylvania for a universal immune cell receptor technology platform invented at the university.

Read more on The Market Herald

Skip to content